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Phagocytosis of non-opsonizedmicroorganisms bymacrophages
initiates innate immune responses for host defense against infec-
tion. Cytosolic phospholipase A2 is activated during phagocytosis,
releasing arachidonic acid for production of eicosanoids, which ini-
tiate acute inflammation. Our objective was to identify pattern rec-
ognition receptors that stimulate arachidonic acid release and
cyclooxygenase 2 (COX2) expression inmacrophages bypathogenic
yeast and yeast cell walls. Zymosan- and Candida albicans-stimu-
lated arachidonic acid release from resident mouse peritoneal
macrophages was blocked by soluble glucan phosphate. In
RAW264.7 cells arachidonic acid release, COX2 expression, and
prostaglandin production were enhanced by overexpressing the
-glucan receptor, dectin-1, but not dectin-1 lacking the cytoplas-
mic tail. Pure particulate (1, 3)--D-glucan stimulated arachidonic
acid release andCOX2 expression, whichwere augmented in aToll-
like receptor 2 (TLR2)-dependent manner by macrophage-activat-
ing lipopeptide-2. However, arachidonic acid release and leukotri-
ene C4 production stimulated by zymosan and C. albicans were
TLR2-independent, whereas COX2 expression and prostaglandin
production were partially blunted in TLR2/ macrophages. Inhi-
bition of Syk tyrosine kinase blocked arachidonic acid release and
COX2 expression in response to zymosan,C. albicans, and particu-
late (1, 3)--D-glucan. The results suggest that cytosolic phospho-
lipase A2 activation triggered by the-glucan component of yeast is
dependent on the immunoreceptor tyrosine-based activation
motif-like domain of dectin-1 and activation of Syk kinase, whereas
both TLR2 and Syk kinase regulate COX2 expression.
Macrophages play an important role in innate immunity, serving as a
first line of defense against microorganisms (1, 2). Resident macro-
phages are widely distributed in tissues and are one of the first cell types
to sense microbial invaders. Macrophages recognize and engulf opso-
nized microorganisms through immunoglobulin and complement
receptors, but they also possess a number of phagocytic receptors that
mediate non-opsonic uptake by binding to specific molecular compo-
nents of microbial surfaces (3–5). Examples of phagocytic pattern rec-
ognition receptors include scavenger receptors, the mannose receptor,
a variety of C-type lectin receptors, and the C-type lectin-like -glucan
receptor dectin-1, which is a receptor for zymosan and fungi (6). Phag-
ocytosis of microorganisms is accompanied by activation of the non-
phagocytic Toll-like receptors (TLR),3 which participate in promoting
inflammatory responses (7, 8). Distinct signaling pathways are triggered
during phagocytosis depending on the receptors engaged by microor-
ganisms influencing functional responses and the survival of intracellu-
lar pathogens (8, 9).
Zymosan particles are cell walls of Saccharomyces cerevisiae that have
been used extensively as a model to study innate immune responses to
fungal infections (10). Intraperitoneal injection of zymosan into mice
induces acute peritonitis and generalized inflammation that can lead to
multiple organ failure (11–13). Non-opsonized zymosan is a potent
activator of mononuclear phagocytes inducing production of pro-in-
flammatory mediators including eicosanoids and cytokines (14–18).
The production of prostaglandin (PG) E2 and leukotriene C4 (LTC4) by
residentmouse peritonealmacrophages occurs withinminutes of intra-
peritoneal zymosan administration and plays a role in mediating early
vascular permeability (11, 19–22).
The release of arachidonic acid for production of eicosanoids by res-
identmouse peritonealmacrophages during phagocytosis of zymosan is
initiated by the activation of Group IVA cytosolic phospholipase A2
(cPLA2) based on results demonstrating that these responses are
blunted in cPLA2/macrophages and by treatmentwith pyrrolidine-1,
an inhibitor of Group IV cPLA2 (23–25). Arachidonic acid released by
cPLA2 is metabolized by 5-lipoxygenase to leukotrienes and by consti-
tutive cyclooxygenase (COX) 1 or inducible COX2 for prostanoid pro-
duction. cPLA2 is regulated post-translationally by increases in intracel-
lular calcium levels and by phosphorylation (26, 27). Calcium binds to
an N-terminal C2 domain that promotes translocation of cPLA2 from
the cytosol to the membrane for access to phospholipid substrate (28–
31). In resident mouse peritoneal macrophages, zymosan activates
mitogen-activated protein kinases, leading to phosphorylation of cPLA2
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forming phagosome during internalization of zymosan (32). The recep-
tors engaged by zymosan that promote cPLA2-mediated release of
arachidonic acid have not been identified in macrophages and are the
focus of this study.
Zymosan is composed primarily of the carbohydrate polymers glucan
and mannan, which are recognized by a variety of receptors on macro-
phages (33, 34). The macrophage mannose receptor, complement
receptor 3, scavenger receptors, the C-type lectin-like receptor, dec-
tin-1, and C-type lectin receptor, specific ICAM (intercellular adhesion
molecule)-3-grabbing nonintegrin-related 1 (SIGNR1), have been
shown to play a role in binding and internalization of zymosan (35–40).
It has previously been reported that monocytes produce eicosanoids
during phagocytosis of zymosan through an unidentified -glucan
receptor (41). Although the complement receptor 3 canmediate uptake
of zymosan through recognition of both glucose andmannosemoieties,
engagement of complement receptor 3 does not induce arachidonic
acid release in resident mouse peritoneal macrophages (42). The -glu-
can receptor dectin-1 has been shown to mediate zymosan-induced
production of cytokines and reactive oxygen species (ROS) in macro-
phages (43, 44). It has recently been demonstrated that dectin-1 acts
cooperatively with TLR2 for mediating production of TNF and IL-12
but can also act independent of TLR2 and mediate production of IL-2,
IL-10, and ROS by a pathway involving Syk kinase (45, 46). To further
understand the mechanisms leading to activation of cPLA2 and eico-
sanoid production,we investigated the role of the-glucan receptor and
TLR2 in mediating zymosan- and Candida albicans-induced arachi-
donic acid release and COX2 expression.
EXPERIMENTAL PROCEDURES
Materials—Pathogen-free ICR mice were obtained from Harlan
Sprague-Dawley and used for all experiments unless otherwise speci-
fied. The TLR4 mutant mouse strain C3H/HeJ and control strain C3H/
HeOuJ were obtained from The Jackson Laboratory. TLR2/ mice
(C57BL/6) were generated as previously described (47), and age-
matched control C57BL/6 mice were obtained from The Jackson Lab-
oratory. All mice were used for macrophage isolation at 4–6 weeks of
age. Zymosan was purchased from Sigma and boiled in phosphate-buff-
ered saline three times before use. Fluorescein- and Texas Red-labeled
zymosan particles were obtained from Molecular Probes. Particulate
-glucan was purified from S. cerevisiae and structurally characterized
by NMR (48). Endotoxin-free water-soluble glucan phosphate was pre-
pared from particulate-glucan as previously described (49).Macroph-
age-activating lipopeptide-2 (MALP-2) was from Alexis Biochemicals.
Mannan was purchased from Sigma. ERTR9 blocking monoclonal anti-
body to amurine analogue of humanDC-SIGN (SIGNR1) was obtained
from Bachem. Lipopolysaccharide (Escherichia coli 0111:B4) was from
List Biologicals. [5,6,8,9,11,12,14,15-3H]Arachidonic acid (specific
activity 100 Ci/mmol) was from PerkinElmer Life Sciences. Fetal bovine
serum (Gemini Bio-Products) was heat-inactivated at 56 °C for 30 min
before use. Dulbecco’s modified Eagle’s medium (DMEM) was from
Cambrex BioScience Walkersville, Inc. Human serum albumin was
obtained from Intergen. TheGroup IVA cPLA2 inhibitor, pyrrolidine-2,
was generously provided by Dr. Michael Gelb. The Src and Syk kinase
inhibitors PP2 and piceatannol, respectively, were obtained from Cal-
biochem. Rabbit polyclonal antibody to Syk (N-19) was obtained from
Santa Cruz Biotechnology, Inc. Phospho-Syk antibody was from Cell
Signaling Technology, Inc. Polyclonal antibody to murine COX2 was
obtained from Caymen Chemical Co.
MacrophageCultures andArachidonic Acid ReleaseAssay—Resident
mouse peritoneal macrophages were obtained by peritoneal lavage
using 5 ml of DMEM containing 10% heat-inactivated fetal bovine
serum, 10 units/ml heparin, 100 g/ml streptomycin sulfate, 100
units/ml penicillin G, and 0.29 mg/ml glutamine (supplemented
DMEM). Cells were plated at a density of 0.5  106/cm2 (48-well plate)
and incubated for 2 h at 37 °C in a humidified atmosphere of 5% CO2 in
air.Wells werewashed twicewith calcium- andmagnesium-freeHanks’
balanced salts solution to remove non-adherent cells. The adherent
macrophages were incubated in supplemented DMEM containing
[3H]arachidonic acid (0.1 Ci/250 l/well) and incubated for 16–18 h
at 37 °C. The cells were washed twice with phosphate-buffered saline
followed by 1 wash with serum-free DMEM containing 0.1% human
serum albumin (stimulation medium) to remove unincorporated
[3H]arachidonic acid and then incubated in stimulation medium. After
stimulation of the macrophages, the culture medium was removed and
centrifuged, and the amount of radioactivity released into the medium
was measured by scintillation counting. The cell-associated radioactiv-
ity was measured after solubilization of the monolayer with 0.1% Triton
X-100. The amount of radioactivity released is expressed as the percent
of the total radioactivity incorporated (cell-associated plus medium).
RAW264.7 macrophages (ATCC number TIB 71) expressing
SIGNR1, murine dectin-1, or dectin-1 with a truncated cytoplasmic tail
were generated as previously described (43). They were plated at 1.5 
105/2 cm2 well (24-well plate) in RPMI containing 10% heat-inactivated
fetal bovine serum, 0.6 mg/ml G418, 100 g/ml streptomycin sulfate,
100 units/ml penicillin G, and 0.29 mg/ml glutamine (supplemented
RPMI). After 6 h they were washed once, incubated in supplemented
RPMI containing [3H]arachidonic acid, and further processed formeas-
uring arachidonic acid release as described above for mouse peritoneal
macrophages.
C. albicans Culture—C. albicans (ATCC 10231) was grown on Sab-
ouraud dextrose agar plates and maintained at 4 °C. The day before the
experiment C. albicans was streaked onto a fresh plate and incubated
overnight at 37 °C. Yeast cells were scraped from the plate and washed
twice in endotoxin-free phosphate-buffered saline.
Phagocytosis Assay—Resident mouse peritoneal macrophages were
plated at 1  106 cells/2 cm2, adhered for 1 h, and washed to remove
non-adherent cells. After overnight incubation in supplemented
DMEM, the cells were washed and then incubated in stimulation
medium containing fluorescein-labeled zymosan (25 particles/cell) for
1 h at 37 °C. After thorough washing to remove unbound zymosan, the
cells were fixed with 1% paraformaldehyde for 15 min. The percentage
of macrophages with cell-associated (bound and internalized) fluores-
cein-labeled zymosan was determined by fluorescence microscopy and
counting 75–100 cells.
Eicosanoid Analysis and Western Blots—Resident mouse peritoneal
macrophages and RAW264.7 cells were plated as described for arachi-
donic acid release assays. After incubation overnight in supplemented
DMEM, the cells were stimulated for 6 h, and amounts of PGE2, PGD2
and LTC4 in the culture medium were quantified by enzyme-linked
immunosorbent assay (Elisa Tech, Aurora, CO). PGD2wasmeasured as
the methoxime derivative as outlined by Cayman Chemical Co. LTC4
was quantified using cysteinyl leukotriene assay reagents, which detect
LTC4, LTD4, and LTE4, using LTC4 as a standard.
For Western blots the cell monolayers were washed twice in ice cold
phosphate-buffered saline and then scraped in lysis buffer (50 mM
Hepes, pH 7.4, 150mM sodium chloride, 10% glycerol, 1%Triton X-100,
1 mM EGTA, 1 mM EDTA, 200 M sodium vanadate, 10 mM tetraso-
dium pyrophosphate, 100 mM sodium fluoride, 300 nM p-nitrophenyl
phosphate, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin,
and 10g/ml aprotinin). After incubation on ice for 30min, lysateswere
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centrifuged at 15,000 rpm for 15 min, and protein concentration in the
supernatant was determined by the bicinchoninic acid method. Lysates
were boiled for 5 min after addition of Laemmli electrophoresis sample
buffer, and then proteins were separated on 10% SDS-polyacrylamide
gels. ForCOX2 analysis, 8g of total lysate proteinwas used, and for Syk
and phospho-Syk analysis, 30 g of protein was used. After transfer to
nitrocellulose membrane, samples were incubated in blocking buffer
(20mMTris-HCl, pH 7.6, 137mMNaCl, 0.05%Tween (TTBS)) contain-
ing 5% nonfat milk for 1 h and then incubated overnight at 4 °C with
polyclonal antibodies (1:1000) to COX2, Syk, or phospho-Syk in TTBS.
The membranes were incubated with anti-rabbit IgG horseradish per-
oxidase antibody (1:5000) inTTBS for 30min at room temperature. The
immunoreactive proteins were detected using the Amersham Bio-
sciences ECL system.
Statistics—Statistics were calculated in GraphPad using unpaired t
test to obtain two-tailed p values.
RESULTS
-Glucan Receptor Mediates Arachidonic Acid Release Induced by
Zymosan and C. albicans—To identify the receptors that mediate
zymosan-induced arachidonic acid release, resident mouse peritoneal
macrophages were incubated with a variety of agents that block recog-
nition of zymosan by specific receptors. As shown in Fig. 1A, arachi-
donic acid release induced by zymosan was dose-dependently blocked
by a highly purified preparation of soluble -(1,3)-glucan phosphate
(49). The number of macrophages undergoing phagocytosis of fluores-
cein isothiocyanate-zymosan decreased from 44  2.6 to 17  1.3%
after preincubation with soluble glucan phosphate (100 g/ml). It has
recently been shown that resident peritoneal macrophages also contain
a mannose binding (mannan-inhibitable) receptor, SIGNR1, which
plays a role in non-opsonic uptake of zymosan and C. albicans and can
act cooperatively with -glucan receptor (40). To determine whether
SIGNR1 plays a role in zymosan-induced arachidonic acid release,
macrophages were preincubated with mannan or a blocking mono-
clonal antibody (ERTR9) to SIGNR1 (Fig. 1B). Arachidonic acid release
was unaffected by mannan or the blocking monoclonal antibody
ERTR9. In additional experiments, zymosan-induced arachidonic acid
release was not blocked by polyinosinic acid (data not shown), an inhib-
itor of macrophage scavenger receptor, which can directly bind -(1,3)-
glucan polymers (39).
The ability of the live fungal pathogenC. albicans to stimulate arachi-
donic acid release in resident mouse peritoneal macrophages was also
investigated. Arachidonic acid release was induced in macrophages
infected with C. albicans using multiplicities of infection (m.o.i.) from 2
to 10 (Fig. 2A). The time course of arachidonic acid release induced by
C. albicans (m.o.i. 5) was determined (Fig. 2B). After the addition of C.
albicans, there was a 10-min lag phase followed by steady accumulation
of arachidonic acid in the medium up to 60 min. Arachidonic acid
release induced by C. albicans was inhibited by preincubation with sol-
uble glucan phosphate but not bymannan or ERTR9 (Fig. 2C). As shown
in Fig. 2D, the cPLA2 inhibitor pyrrolidine-2 blocked C. albicans-in-
duced arachidonic acid release to basal levels, implicating a role for
Group IVA cPLA2 (50). The results demonstrate that a receptor that
recognizes -glucan on zymosan and C. albicansmediates cPLA2 acti-
vation and arachidonic acid release.
FIGURE 1. -Glucan receptor mediates zymosan-stimulated arachidonic acid
release. Mouse peritoneal macrophages labeled with [3H]arachidonic acid were prein-
cubated for 15 min with soluble glucan phosphate (A) or blocking monoclonal antibody
(ERTR9) to SIGNR1, soluble glucan phosphate (S-GP), or mannan (Man) (B). After an addi-
tional incubation for 45 min in the absence (open bars) or presence (gray bars) of zymo-
san (20 particles/cell), the amount of [3H]arachidonic acid released was determined and
expressed as the % of the total label incorporated (cells plus medium). The results are the
mean of three experiments S.E. (A) or the average of two experiments S.D. (B).
FIGURE 2. C. albicans stimulates cPLA2-mediated arachidonic acid release through a
-glucan receptor. The release of [3H]arachidonic acid was determined after a 60-min
incubation of mouse peritoneal macrophages with the indicated m.o.i. of C. albicans (A),
at the indicated times in control (open circles) or C. albicans (m.o.i. 5)-infected macro-
phages (closed circles) (B), after preincubation (using concentrations shown in Fig. 1B) for
15 min with blocking monoclonal antibody (ERTR9) to SIGNR1, soluble glucan phosphate
(S-GP), or mannan (Man) followed by a 60-min incubation without (open bar) or with C.
albicans (m.o.i. 5) (gray bars) (C), or after a 15-min preincubation with 5 M pyrrolidine-2
followed by 60-min incubation without (open bars) or with C. albicans (m.o.i. 5) (gray bars)
(D). The amount of [3H]arachidonic acid released in A is expressed as the % of the total
label incorporated (cells plus medium) after subtracting the % release from unstimulated
cells. Results in A and B are the mean of three experiments S.E., those in C are the
average of triplicate samples S.D. of a representative experiment, and those in D are
the average of two experiments S.D.
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Role of Dectin-1 in Mediating Arachidonic Acid Release, COX2
Expression, and Prostaglandin Production—Dectin-1 has been identi-
fied as the -glucan receptor on macrophages that mediates the pro-
duction of pro-inflammatory cytokines induced by zymosan and live
fungi (38, 43). RAW264.7 cells lines stably expressing dectin-1 or
SIGNR1 were used to determine whether these receptors mediate
arachidonic acid release in response to zymosan. RAW264.7 cells nor-
mally express very low levels of these receptors (43). As shown in Fig. 3,
arachidonic acid releasewas stimulated by ionomycin to a similar extent
in vector control cells and in RAW264.7 cells overexpressing dectin-1
and SIGNR1. In contrast, arachidonic acid release in response to zymo-
san and C. albicans was greater in RAW264.7 cells overexpressing dec-
tin-1 compared with vector control cells or cells expressing SIGNR1 or
truncated dectin-1. Only in RAW264.7 cells overexpressing dectin-1
was expression of COX2 induced by zymosan and C. albicans (Fig. 3B).
RAW264.7 cells overexpressing dectin-1 also producedmore PGD2, the
major prostanoid made by this macrophage cell line, than cells overex-
pressing SIGNR1 or truncated dectin-1. Zymosan andC. albicans stim-
ulated a low level of arachidonic acid release and PGD2 production in
vector control cells but not in cells expressing SIGNR1 or truncated
dectin-1. The reason for this is not known, but since SIGNR1 and trun-
cated dectin bind the fungal agents but do not signal for arachidonic
acid release, they may have a dominant negative effect. The lack of
stimulation in cells expressing truncated dectin-1 suggests that the
ITAM-like motif in the cytoplasmic tail of dectin-1 is required for
cPLA2 activation and COX2 expression in response to zymosan and
C. albicans.
Zymosan andC. albicans are complex agonists that may engagemul-
tiple receptors to provide signals for activating cPLA2. To investigate the
ability of the -glucan receptor to mediate arachidonic acid release, we
used a highly purified endotoxin-free preparation of particulate -glu-
can (P-G) that had been thoroughly characterized by NMR (48). P-G
stimulated a dose-dependent release of arachidonic acid from mouse
peritoneal macrophages, resulting in a 14% release at a concentration of
100g/ml, demonstrating that cross-linking the-glucan receptorwith
purified particulate -glucan induces signals for cPLA2 activation (Fig.
4A). To determine whether particle internalization is required for
cPLA2-mediated arachidonic acid release by P-G, zymosan, and
C. albicans, resident mouse peritoneal macrophages were treated with
cytochalasin D (Fig. 4B). The release of arachidonic acid induced by
FIGURE 3. Dectin-1 mediates zymosan- and C. albicans-induced arachidonic acid
release, COX2 expression, and prostanoid production. A, RAW264.7 cells expressing
dectin-1, SIGNR1, truncated dectin-1, and vector controls were labeled overnight with
[3H]arachidonic acid. After washing, the amount of [3H]arachidonic acid release at 60
min from unstimulated cells (open bars), cells stimulated with zymosan (20 particles/cell)
(light gray bars), C. albicans (m.o.i. 5) (dark gray bars), or 1 M ionomycin (black bars) was
determined. Results are the mean of three experiments S.E. RAW264.7 cells expressing
dectin-1, SIGNR1, truncated dectin-1 vector controls were incubated either without
(unstimulated (US)) or with zymosan (Zym) (20 particles/cell) or C. albicans (CA; m.o.i. 5),
and the level of COX2 expression in cell lysates was determined by Western blot (B), or
the amount of PGD2 in the culture supernatant was determined after stimulation of cells
for 6 h (C).
FIGURE 4. Stimulation of cPLA2-mediated arachidonic acid release by purified P-G.
The release of [3H]arachidonic acid was determined after a 60-min incubation of mouse
peritoneal macrophages with the indicated concentrations of P-G (A) or after a 30-min
preincubation with 4 M cytochalasin D followed by a 60-min incubation without
(unstimulated (US)) or with zymosan (20 particles/cell), C. albicans (m.o.i. 5), or P-G (100
g/ml) (B). The results are the mean of three experiments S.E.
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C. albicans and zymosan was inhibited by 60 and 27%, respectively, in
macrophages treated with cytochalasin D, but release induced by P-G
was unaffected. Cytochalasin D did not inhibit arachidonic acid release
from macrophages stimulated with ionomycin (not shown). The 1-h
pretreatment of peritoneal macrophages with 4 M cytochalasin D and
maintenance at this concentration during stimulation prevented inter-
nalization of Texas Red zymosan (data not shown) as previously
reported (51). The results demonstrate that particle internalization is
not essential for cPLA2 activation through the -glucan receptor,
although internalization of C. albicans and to a lesser extent zymosan
enhances arachidonic acid release.
Role of TLRs in Mediating Arachidonic Acid Release, COX2 Expres-
sion, and Eicosanoid Production—Dectin-1 promotes -glucan-
dependent internalization of zymosan and mediates TLR2-dependent
and -independent responses in macrophages and dendritic cells. TNF
and IL-12 production triggered by dectin-1 are TLR2-dependent,
whereas IL-2, IL-10, and ROS production are independent of TLR2
(43–46). Our results using purified P-G suggest that engagement of
the -glucan receptor itself provides signals that activate cPLA2; how-
ever, it is possible that TLR2 contributes to cPLA2 activation in response
to zymosan and C. albicans. To investigate whether a soluble TLR2
agonist can induce arachidonic acid release or enhance the response to
engagement of the -glucan receptor, peritoneal macrophages were
treated with synthetic MALP-2, a lipoprotein from Mycoplasma fer-
mentans that has been shown to be a specific activator of TLR2 (52). As
shown in Fig. 5A, MALP-2 was a very weak agonist and induced only a
small increase in arachidonic acid release at 0.1–1.0 ng/ml. When
MALP-2 was added together with P-G, a greater than additive effect
on arachidonic acid release was observed. The stimulation of arachi-
donic acid release by P-G and P-G together withMALP-2 was inhib-
ited by pyrrolidine-2, confirming a role for cPLA2 (Fig. 5B). The results
suggest that engagement of the -glucan receptor by purified P-G
more effectively triggers cPLA2 activation than engagement of TLR2,
but signals from both receptors can act together to enhance activation
of cPLA2.
The contribution of TLRs in mediating cPLA2 activation in response
to zymosan, C. albicans, and P-G was investigated by using resident
mouse peritoneal macrophages isolated from TLR2 and TLR4 knock-
out mice. Both TLR2 and TLR4 have been implicated in murine
defenses againstC. albicans (53, 54). As shown in Fig. 6A, TLR4 was not
required for arachidonic acid release, which was slightly enhanced in
TLR4/ macrophages in response to P-G, zymosan, and C. albicans.
We did not observe significant stimulation of arachidonic acid release
fromwild type orTLR4/macrophages in response to lipopolysaccha-
ride, consistentwith previous reports that endotoxin is a poor inducer of
arachidonic acid release in residentmouse peritonealmacrophages (55).
The reason for the enhanced response is not known, but a similar
enhancement of IL-6 production in TLR4-deficient macrophages
infected with Helicobacter has also been observed (56).
Arachidonic acid release was also measured in peritoneal macro-
phages isolated from WT and TLR2/ mice (Fig. 6B). TLR2 was not
required for arachidonic acid release in response to zymosan, C. albi-
cans, or P-G.However, the ability of the solubleTLR2 agonistMALP-2
to enhance arachidonic acid release when used together with P-Gwas
dependent on TLR2, since the extent of arachidonic acid release in
response to MALP-2 and P-G in TLR2/ macrophages was signifi-
cantly attenuated to the level observed with P-G alone.
The ability of the particulate agonists (zymosan, C. albicans, P-G)
andMALP-2 to induce COX2 expression and eicosanoid production in
wild type and TLR2/ macrophages was compared. All the agonists
increased COX2 expression in TLR2/ macrophage after treatment
for 6 h (Fig. 7A). COX2 expression was partially suppressed in TLR2/
macrophages treated for 6 h with zymosan, C. albicans, and P-G (Fig.
7A), which correlated with decreased PGE2 production (Fig. 7B).
MALP-2 induced COX2 expression in a TLR2-dependent manner (Fig.
7A); however, MALP-2 did not significantly increase PGE2 production
(Fig. 7B) presumably due to its poor ability to activate cPLA2 and pro-
vide arachidonic acid. However, as observed for arachidonic acid
release, COX2 expression and PGE2 production were greater in macro-
phages treated with both P-G and MALP-2 than with either agonist
alone, and these enhanced responses by MALP-2 were TLR2-depend-
ent. The effect of the agonists on LTC4 productionwas also determined.
The relative levels of LTC4 produced by TLR2/ macrophages was
similar to the relative amounts of arachidonic acid released (compare
with Fig. 6B). Also similar to arachidonic acid release, LTC4 production
was independent of TLR2 in response to zymosan, C. albicans, and
P-G but was lower in TLR2/ macrophages in response to P-G
together with MALP-2. The results indicate that transcriptional regu-
lation of COX2 is partially dependent on TLR2, but regulation of cPLA2
and 5-lipoxygenase, which involves posttranslational processes, is
TLR2-independent.
FIGURE 5. Augmentation of P-G-induced arachidonic acid release by the TLR2 ago-
nist MALP-2. The release of [3H]arachidonic acid was determined after a 60-min incuba-
tion of mouse peritoneal macrophages with the indicated concentrations of MALP-2
either alone or together with 100 g/ml P-G (A) or after a 15-min preincubation with 5
M pyrrolidine-2 followed by a 60-min incubation without (unstimulated (US)) or with
100 g/ml P-G alone and together with 1 ng/ml MALP-2 (B). The results are the mean of
three experiments S.E. In A, the asterisk indicates a significant increase (p  0.05) for
cells treated with MALP-2 alone compared with untreated control cells (open bar) and for
cells treated with MALP-2 together with P-G compared with cells treated with P-G
alone.
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Inhibition of Src and SykKinases Blocks Arachidonic Acid Release and
COX2 Expression—It has recently been shown that TLR2-independent
responses induced by zymosan engagement of dectin-1 in dendritic cells
and in certain populations of macrophages require Syk kinase (45, 46).
Inmacrophages, activation of ROS production by zymosan requires Src
and Syk kinases; however, phagocytosis of zymosan is Syk-independent
(46, 57). Because we found that TLR2 was not required for -glucan
receptor-dependent activation of arachidonic acid release and only par-
tially required for COX2 expression, the role of Src and Syk kinases was
investigated. As shown in Fig. 8A, the Src kinase inhibitor PP2 sup-
pressed arachidonic acid release in response to zymosan. In contrast,
arachidonic acid release stimulated by A23187 was not affected by PP2
(data not shown). The Syk kinase inhibitor piceatannol inhibited arachi-
donic acid release and COX2 expression in peritoneal macrophages
treated with zymosan, C. albicans, and P-G (Fig. 8, B and C). We
confirmed that zymosan stimulated phosphorylation of Syk, a measure
of Syk activation, and this was blocked by piceatannol (Fig. 8B, inset).
The results suggest that cPLA2 activation and COX2 expression stimu-
lated by the -glucan receptor involves tyrosine phosphorylation of the
ITAM-like motif of dectin-1 and activation of Syk kinase.
DISCUSSION
The polysaccharide-rich cell walls of yeast are potent inducers of
acute inflammation, as reflected in the ability of zymosan to promote
complement activation and production of eicosanoids, ROS, and cyto-
kines (15, 33, 58–64). The zymosan-induced mouse peritonitis model
has all the key features of acute inflammation including increased vas-
cular permeability, pain, leukocyte influx, and eicosanoid production
(11, 12, 20). In the peritonitis model the production of eicosanoids by
resident peritoneal macrophages peaks within minutes after zymosan
administration and contributes to pain, edema formation, and leuko-
cyte recruitment (20–22). In vitro studies have confirmed the ability of
resident peritoneal macrophages to release large amounts of arachi-
donic acid and eicosanoids during phagocytosis of zymosan (62, 63). In
fact resident mouse peritoneal macrophages produce much greater
amounts of eicosanoids than elicited/activated peritonealmacrophages,
suggesting that lipid mediator production by resident tissue macro-
phages that first encounter microorganisms plays an important role in
initiating acute inflammatory responses and innate immunity (65–67).
FIGURE 6. Role of TLRs in regulating arachidonic acid release. Resident mouse peri-
toneal macrophages isolated from TLR4 (A) or TLR2 (B) knock-out (black bars) and wild
type (open bars) mice were labeled with [3H]arachidonic acid and then stimulated with
zymosan (Zym; 20 particles/cell), lipopolysaccharide (LPS; 0.5 g/ml), C. albicans (C.alb)
(m.o.i. 5), P-G (100 g/ml), MALP-2 (1 ng/ml), or P-G (100 g/ml) together with MALP-2
(1 ng/ml). Release of [3H]arachidonic acid was measured at 60 min from unstimulated
(US) and stimulated cells. The asterisk in B indicates a significant decrease (p  0.005) for
TLR2/ macrophages treated with P-G plus MALP-2 compared with TLR2/
macrophages.
FIGURE 7. Role of TLR2 in regulating COX2 expression and eicosanoid production.
Resident peritoneal macrophages isolated from TLR2/ and TLR2/ mice were incu-
bated overnight as described under “Experimental Procedures” and then stimulated for
1 or 6 h with zymosan (Zym; 20 particles/cell), C. albicans (C.alb) (m.o.i. 5), P-G (100
g/ml), MALP-2 (1 ng/ml), or P-G (100 g/ml) together with MALP-2 (1 ng/ml). A, cells
stimulated for 6 h were analyzed for COX2 by Western blotting and for levels of PGE2 (B)
and LTC4 (C) in the culture medium. The results in B and C are the average of 5 and 3
experiments S.E., respectively. The asterisk indicates a significant decrease (p  0.05) in
PGE2 production in cells from TLR2
/ compared with TLR2/ mice. US, unstimulated.
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Zymosan-induced release of arachidonic acid from peritoneal macro-
phages is mediated by cPLA2, which is the only sn-2 arachidonic acid-
selective mammalian PLA2 that has been identified (27, 68).
A number of receptors on macrophages have been implicated in
mediating phagocytosis of non-opsonized zymosan through recogni-
tion of carbohydrate moieties in the yeast cell wall. A -glucan receptor
was previously shown to be responsible for zymosan-induced arachi-
donic acid release and eicosanoid production in rodent and human
mononuclear phagocytes, as we observed in resident mouse peritoneal
macrophages (64, 69). Complement receptor 3, scavenger receptor
AI/II, and lactosylceramide on macrophages can bind -glucan; how-
ever, recent studies demonstrate that the C-type lectin-like receptor
dectin-1 is the principal -glucan receptor on macrophages that medi-
ates biological responses such TNF and ROS production (36, 39, 43,
44, 51, 70).Our findings that soluble glucan-phosphate blocks zymosan-
and C. albicans-induced arachidonic acid release and that overexpres-
sion of dectin-1 in RAW264.7 macrophages enhances arachidonic acid
release suggests a role for dectin-1 in cPLA2 activation by zymosan and
C. albicans. In addition, our results demonstrate that engagement of
dectin-1 by zymosan andC. albicans promotes expression of COX2 and
increased prostaglandin production. Dectin-1 is widely expressed in
human and mouse monocyte/macrophage populations (71, 72). How-
ever, resident mouse peritoneal macrophages express relatively low lev-
els compared with mouse alveolar macrophages or thioglycolate-elic-
ited macrophages (72, 73). Dectin-1 is increased on resident mouse
peritoneal macrophages after 1 day in culture (72); however, we
observed that zymosan-stimulated arachidonic acid release is blocked
to a similar extent by soluble glucan phosphate in resident mouse peri-
toneal macrophages cultured for 4 (not shown) or 24 h after isolation.
C. albicans and other opportunistic fungal pathogens have been
shown to induce eicosanoid production by macrophages. Arachidonic
acid release from mouse alveolar macrophages and human monocytes
incubated with live C. albicans was shown to be partially blocked by
-mannan purified from C. albicans and blocked to a lesser extent with
-glucan, suggesting a role formannose and-glucan receptors (74, 75).
We found that soluble glucan phosphate blocked arachidonic acid
release from resident mouse peritoneal macrophages incubated with
C. albicans to a large extent (90%), but -mannan had no effect, sug-
gesting a primary role for the -glucan receptor. It was originally
thought that the mannose receptor on alveolar macrophages was the
primary receptor for the opportunistic fungus Pneumocystis carinii,
which also stimulates arachidonic acid release (76). However, the
absence of the mannose receptor in mice does not increase susceptibil-
ity to either P. carinii or C. albicans (77, 78), and a role for the -glucan
receptor, dectin-1, in the recognition of P. carinii, C. albicans, and Coc-
cidioides posadasii has emerged (79, 80). Unlike zymosan particles, the
-glucan component of live C. albicans is buried beneath the outer cell
wall components; however, it has recently been shown that soluble dec-
tin-1 binds to discrete patches on the yeast form of C. albicans corre-
sponding to bud scars, suggesting that these are regions of exposed
-glucan (81).
Tyrosine phosphorylation of an ITAM-like motif in the cytoplasmic
tail of dectin-1 is required for internalization of zymosan (43, 44). We
found that the internalization of zymosan was not essential for arachi-
donic acid release, similar to results for zymosan-induced TNF pro-
duction (43). When particle internalization was blocked with cytocha-
lasin D, arachidonic acid release was attenuated to a greater extent with
C. albicans (60%) than with zymosan (27%), and the response to P-G
was completely unaffected. These results suggest a correlation with
accessibility of -glucan and the requirement for internalization.
Although there is evidence that discrete regions of C. albicans bind
dectin-1 (81), internalization of C. albicansmay expose more -glucan
for interaction with dectin-1, enhancing activation of cPLA2.
Dectin-1 cooperates with TLR2, which is recruited to macrophage
phagosomes containing zymosan and is required for production of
TNF (43, 44). In addition, TLR2 is required for host defense to patho-
genic fungus andmediates TNF production by theC. albicans cell wall
component phospholipomannan (82). Zymosan has also been shown to
directly bind to TLR2 (83). However, the component on zymosan that
activates TLR2 has not been identified.Hot alkali treatment depletes the
TLR2 activating component of zymosan, which eliminates NFB acti-
FIGURE 8. Inhibition of Syk blocks arachidonic acid release and COX2 expression.
Peritoneal macrophages (from ICR mice) labeled with [3H]arachidonic acid were prein-
cubated for 30 min with 10 M PP2 (A) or 25 M piceatannol (Pic) (B) and then stimulated
with zymosan (10 particles/cell), C. albicans (C.alb) (m.o.i. 5), or 100 g/ml P-G. Release
of [3H]arachidonic acid was measured at 60 min from unstimulated (US) and stimulated
cells. B, inset, phospho (P)-Syk or total Syk was analyzed by Western blot in lysates of
unstimulated or zymosan-stimulated (10 particles/cell, 60 min) macrophages that had
been preincubated for 15 min with or without piceatannol (25 M). C, peritoneal macro-
phages were stimulated for 6 h with zymosan (Zym; 10 particles/cell), C. albicans (C.alb)
(m.o.i. 5), or 100 g/ml P-G in the presence or absence of piceatannol, and cell lysates
were analyzed for COX2 expression by Western blotting.
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vation but not dectin-1 binding or zymosan internalization (44). The
ability of a soluble TLR2 agonist to synergize with depleted zymosan for
induction of cytokine production demonstrates that signals from dec-
tin-1 and TLR2 can act together for enhanced responses (44). Similarly
we found that the soluble TLR2 agonist MALP-2, which on its own is a
poor activator of cPLA2, augments P-G-induced arachidonic acid
release in a TLR2-dependent manner. However, stimulation of cPLA2-
mediated arachidonic acid release by zymosan, C. albicans, and P-G is
independent of TLR2. The ability ofMALP-2 but not the TLR2-activat-
ing component of zymosan to contribute to cPLA2 activation may be
explained by the recent finding that CD36 is a TLR2 adaptor protein
required for sensing the diacylated bacterial lipopeptide MALP-2 but
not triacylated lipopeptides or theTLR2 activating component of zymo-
san (84). Consequently, our results suggest that co-engagement ofCD36
and TLR2 promotes signals that can augment cPLA2 activation. This is
consistent with our previous observation that oxidized low density
lipoprotein, a CD36 ligand, induces a small increase in arachidonic acid
release in mouse peritoneal macrophages (85).
The production of LTC4 by resident peritoneal macrophages in
response to zymosan, C. albicans, and P-G is also independent of
TLR2. There are similarities in the regulation of cPLA2 and 5-lipoxyge-
nase, which contains a C2-like domain and exhibits calcium-dependent
membrane binding and may be regulated by phosphorylation. In con-
trast, the expression of COX2 and PGE2 production induced by zymo-
san, C. albicans, and P-G is partially dependent on TLR2. That the
TLR2-dependent effect on COX2 expression was observed with puri-
fied P-G suggests “cross-talk” between the -glucan receptor andmay
not be dependent on the TLR2 ligand in zymosan or C. albicans.
The cytoplasmic tail of dectin-1 is required for zymosan-induced
arachidonic acid release, but internalization of zymosan is not essential,
suggesting a role for the ITAM-like motif of dectin-1 in providing sig-
nals for cPLA2 activation. We also demonstrated that zymosan induces
phosphorylation of endogenous Syk in resident peritoneal macro-
phages. Although dectin-1 does not have a classic ITAM, engagement of
dectin-1 by zymosan activates Src and Syk kinases, which are required
for zymosan-induced ROS production in macrophages (46). Thus,
NADPH oxidase and cPLA2 are activated by similar mechanisms in
macrophages through the -glucan receptor involving the Src and Syk
kinase pathway but not TLR2 (44, 46). Syk kinase has also been reported
to be required for cPLA2 activation in mast cells stimulated by antigen
via the immunoglobulin E receptor (86). Syk activation by antigen pro-
motes increases in intracellular calcium and activation of mitogen-acti-
vated protein kinases, both of which are important regulators of cPLA2
(86, 87). Zymosan also induces an increase in intracellular calcium and
activation of mitogen-activated protein kinases, which are involved in
regulating cPLA2 in mouse peritoneal macrophages (25, 88, 89). There-
fore, Syk kinase is a key regulator for cPLA2 activation by classical ITAM
in immunoreceptors and the atypical ITAM in the lectin-like receptor,
dectin-1.
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